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Background: Recent studies have demonstrated that sublobar resection is not inferior to lobectomy for peripheral
early lung cancer with ground-glass opacification. However, the effect of sublobar resection on solid-type early lung
cancer is controversial. The aim of this study was to compare clinical outcomes of patients who have undergone
sublobar resection or lobectomy for solid-type, early-stage, non-small cell lung cancer (NSCLC).
Methods: This study was a retrospective review of the records of patients who underwent lobectomy or sublobar
resection between March 2000 and September 2010 for clinical stage IA NSCL. Patients with pure ground-glass
opacities or death within 30 days after surgery were excluded. Disease-free interval, survival, and prognostic factors
were analyzed.
Results: Thirty-one patients and 133 patients underwent sublobar resection and lobectomy, respectively. There
were significant differences in age (P <0.001), cardiovascular disease (P = 0.001), and diffusing capacity of the lung
for carbon monoxide (DLCO) (P <0.001). The patients with lobectomy had a significantly longer disease-free interval
(P <0.001) and survival (P = 0.001). By multivariate analysis, sublobar resection (P = 0.011), lymphatic vessel invasion
(P = 0.006), and number of positive lymph nodes (P = 0.028) were predictors for survival. Sublobar resection
(P <0.001), visceral pleural invasion (P = 0.002), and lymphatic vessel invasion (P <0.001) were predictors for disease-free
interval.
Conclusions: Lobectomy should remain the standard surgical procedure for solid-type, clinical stage IA, NSCLC.
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Lung cancer is the most common cause of cancer-
related death worldwide. Surgical resection for stage IA,
non-small cell lung cancer (NSCLC) is the best option
for curative treatment, with a 5-year survival rate ap-
proaching 70%. Lobectomy with mediastinal lymph node
dissection has been considered standard treatment. How-
ever, some early-stage patients undergo sublobar resection
because of poor cardiopulmonary reserve or other medical
comorbidities. Sublobar resection consists of segmen-
tectomy or wedge resection with or without lymph node
dissection.
For ground-glass opacities on imaging, which have been
found to be slowly growing and noninvasive tumors [1],* Correspondence: jaekpark@catholic.ac.kr
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reproduction in any medium, provided the orsublobar resection is not inferior to lobectomy. However,
in solid-type or solid-dominant early lung cancer, the effi-
cacy of sublobar resection is controversial. Several studies
have revealed that sublobar resection was associated with
poor outcomes and higher recurrence rates [2,3]. How-
ever, because of advances in imaging study and surgical
technique, sublobar resection is a reasonable approach for
patients with early lung cancers that are 2 cm or smaller
by recent study [4]. We studied the clinical outcomes of
patients with solid-type early lung cancers who underwent
sublobar resection or lobectomy.Methods
Patients
This was a retrospective review that was approved by
the Institutional Review Board at the Seoul St. Mary’s
Hospital (Republic of Korea). Between March 2000 and
September 2010, 204 patients had clinical stage IAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.










Age 62.53 ± 9.12 69.65 ± 10.94 <0.001
Sex male 83 (62.41) 22 (70.97) 0.413
Hypertension 49 (36.84) 14 (45.16) 0.417
Diabetes mellitus 19 (14.29) 8 (25.81) 0.175
Cardiovascular disease 8 (6.02) 9 (29.03) 0.001
Cerebrovascular accident 3 (2.26) 3 (9.68) 0.082
Interstitial lung disease 11 (8.27) 11 (19.35) 0.096
COPD 6 (4.51) 4 (12.90) 0.096
FEV1 2.41 ± 0.57 2.16 ± 0.66 0.087
DLCO 98 ± 19.78 75 ± 15.88 <0.001
PET SUVmax 4.81 ± 3.41 5.85 ± 4.45 0.386
Data presented as the mean (standard deviation) or frequencies and
percentages as appropriate.
COPD, chronic obstructive pulmonary disease; DCLO, diffusing capacity of the
lung for carbon monoxide; FEV1, forced expiratory volume-one second; PET
SUVmax, maximum standardized uptake value on positron emission tomography.
Data presented as mean ± SD or n (%) as appropriate. Continuous variables were
compared using Mann-Whitney U test and categorical variables were tested using
Chi-square test or Fisher exact test.
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fication for lung cancer. Patients with ground-glass opa-
city on imaging, a tumor with predominant ground-glass
opacification, or who died within 30 days after surgery
were excluded. A total of 38 patients showed ground-
glass opacity or ground-glass opacity dominant lesion
(GGO >50%) on chest tomography. Two patients died
from pneumonia and acute respiratory distress syn-
drome after operation. A total of 164 patients were in-
cluded in the study. Preoperative assessments included
chest computed tomography (CT), abdominal CT, brain
magnetic resonance imaging (MRI) and bone scanning
with neck sonography. Since 2004, the routine preopera-
tive assessment has included chest CT, positron emission
tomography (PET)-CT, bone scanning, brain MRI, and
bronchoscopy. Thirty-one patients underwent sublobar re-
section, and 133 patients underwent lobectomy. Sublobar
resection was considered for severe underlying lung dis-
ease (interstitial lung disease, obstructive lung disease),
poor cardiac function (valvular heart disease, coronary dis-
ease), aortic dissection or aneurysm and other underlying
malignancy. Of patients undergoing sublobar resection,
12 patients underwent segmentectomy, and 19 patients
underwent wedge resection with or without lymph node
dissection. Pathologic features and clinical outcomes were
compared between the two patient groups. Recurrence
was defined as local or extrathoracic metastasis and was
based on clinical and pathological evidence. Patients with
pathologic stage II or III received adjuvant chemotherapy
or chemoradiotherapy. The patients with sublobar re-
section received radiotherapy if the resected margin was
positive.
Statistical analysis
All statistical analyses were carried out using SPSS version
18 (SPSS Inc., Chicago, USA). Continuous variables were
compared using the Mann-Whitney U test, and categor-
ical variables were compared using the Chi-square test
and the Fisher exact test. Disease-free intervals and overall
survival rates were estimated using the Kaplan-Meier
method and compared using the log-rank test. Variables
associated with recurrence and survival were determined
using the Cox proportional hazards model. Before ap-
plication of the Cox proportional hazards model, the
proportionality assumption was checked. Multivariate
analysis for disease-free interval and survival was also
performed using the Cox proportional hazards model.
Variables with a P value less than 0.05 by univariate
analysis were finally evaluated by multivariate analysis
using forward selection.
Results
Records of a total of 164 patients were reviewed in this
study. High-risk patients tended to undergo sublobarresection (Table 1). Sublobar resection was significantly
associated with older age, more cardiovascular disease
(P = 0.001), and low diffusing capacity of the lung for
carbon monoxide (DLCO). The mean age of lobectomy
patients and sublobar resection patients was 62.53 and
69.65 years, respectively (P <0.001). Eight patients (6%)
with cardiovascular disease underwent lobectomy, and
nine patients (29%) underwent sublobar resection. DLCO
was significantly lower in the sublobar resection patients
(P <0.001).
Pathologic variables are listed in Table 2. Adenocar-
cinoma was the most common tumor cell type; how-
ever, the fraction of adenocarcinomas was significantly
higher in the lobectomy patients (P = 0.012). There was
no significant difference in the degree of tumor differ-
entiation between the two groups. The mean tumor size
of the lobectomy and sublobar resection patients was
2.19 cm and 1.99 cm, respectively (P = 0.239). Among
lobectomy patients, the mean bronchial margin was
3.51, and among sublobar resection patients, the mean
margin was 0.95 cm (P <0.001). The number of excised
lymph nodes was significantly higher in the lobectomy
group (P <0.001). Twenty patients with lobectomy (15%)
had pathologic nodal disease (P <0.015). The number of
positive lymph nodes was significantly higher in the lob-
ectomy patients (P = 0.019). Although the number of
metastatic mediastinal lymph nodes was higher in the
lobectomy patients, the difference was not significant.
There was no significant difference in the numbers of
Table 2 Pathologic data of solid-type, clinical stage IA,











Adenocarcinoma 109 (82.0) 18 (58.1)
Squamous 16 (12.0) 10 (32.36)
Others 8 (6.0) 3 (9.7)
Differentiation 0.116
Well 51 (38.4) 6 (19.4)
Moderate 65 (48.9) 21 (67.7)
Poor 17 (12.8) 4 (12.9)
Tumor size 2.19 ± 0.75 1.99 ± 0.75 0.239
p T stage 0.694
pT1a 67 (50.4) 17 (54.8)
Margin 3.51 ± 2 0.95 ± 1.16 <0.001
Positive margin 1 (0.8) 7 (22.6) <0.001
Visceral pleural invasion 15 (11.3) 3 (6.7) 1.000
Lymphatic vessel invasion 29 (21.8) 4 (12.9) 0.450
Blood vessel invasion 3 (2.3) 0 (0) 1.000
Number of LN harvest 10.50 ± 7.6 1.74 ± 5.09 <0.001
LN metastasis 20 (15.0) 0 (0) 0.015
Number of positive LNs 0.53 ± 1.90 0 (0) 0.019
N2 positive 10 (7.5) 0 (0) 0.211
p Stage 0.156
p Stage I 112 (84.2) 30 (96.8)
p Stage II 11 (8.3) 0 (0)
p Stage III 10 (7.5) 1 (3.2)
Recurrence 35 (26.3) 19 (61.3) <0.001
Lung to lung metastasis 8 (6) 6 (19.4)
Margin 4 (3) 4 (12.9)
Mediastinal lymph node 6 (4.5) 5 (16.1)
Distant metastasis 17 (12.8) 4 (12.9)
Data presented as the mean (standard deviation) or frequencies and
percentages as appropriate.
LN, lymph nodes. Data presented as mean ± SD or n (%) as appropriate.
Continuous variables were compared using Mann-Whitney U test, and
categorical variables were tested by Chi-square test or Fisher exact test.
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vasion, and blood vessel invasion between the two groups.
All patients were followed until recurrence and death or
loss to follow-up (F/U). The median F/U period for lobec-
tomy and sublobar resection patients was 40 months
and 30 months, respectively. There was recurrence in 35
lobectomy patients (26%) and 19 sublobar resection pa-
tients (61%; P <0.001). Local recurrence rate was also sig-
nificant higher in the patients with sublobar resection(7.5% in lobectomy versus 29% in sublobar resection;
P <0.001). The disease-free interval of lobectomy patients
was significantly longer (P <0.001; Figure 1a). By univari-
ate analysis, cardiovascular disease, sublobar resection, vis-
ceral pleural invasion, positive margin, lymphatic vessel
invasion, and lymph node metastasis were significant pre-
dictors of recurrence. By multivariate analysis, sublobar re-
section (P <0.001), visceral pleural invasion (P = 0.002),
and lymphatic vessel invasion (<0.001) were significant for
recurrence (Table 3).
Sublobar resection was associated with high overall
mortality. (P = 0.001; Figure 1b). Estimated 5-year survival
rate was 81% in the lobectomy group and 41% in the sub-
lobar resection group. Univariate analysis for predictors of
survival revealed that age, cardiovascular disease, sublobar
resection, lymphatic vessel invasion, number of lymph
node metastases, and pathological mediastinal lymph node
metastasis were statistically significant. Sublobar resection
(P = 0.011), lymphatic vessel invasion (P = 0.006), and
number of metastatic lymph nodes (P = 0.028) were sig-
nificant predictors for overall survival by multivariate
analysis (Table 4). Only sublobar resection and lymph-
atic vessel invasion were significant for both recurrence
and survival in our study.
In a subgroup analysis of 83 patients with tumors
smaller than 2 cm, lobectomy was significantly associ-
ated with better clinical outcomes than sublobar resection
(Figure 2). We also evaluated clinical outcomes between
segmentectomy and wedge resection in 31 patients with
sublobar resections. There was no significant difference for
disease-free interval (P = 0.252) and survival (P = 0.821) be-
tween segmentectomy and wedge resection.
There was no significant difference for survival (P =
0.979) and disease-free interval (P = 0.707) according to
tumor size (pT1a versus pT1b) in sublobar resection.
Multivariate analysis after exclusion of the eight patients
with incomplete resection demonstrated that sublobar
resection was the only independent risk factor for overall
survival in subgroup analysis (P = 0.038, Hazard ratio:
3.01, 95% confidence interval, 1.06 to 8.58).
Discussion
Lung cancer is one of the most common malignant tu-
mors worldwide, with a poor prognosis despite multi-
modality management [5]. However, 5-year survival rates
of up to 70% have been achieved after surgical treatment
for patients with stage I lung cancers [6]. Pneumonectomy,
with high morbidity and mortality, was the standard surgi-
cal treatment in the 1940s [7]. Since the 1950s, lobar resec-
tion plus mediastinal lymph node dissection has become
the standard surgical treatment for lung cancer [8,9].
Patients with early lung cancer who are not suit-
able for lobar resections are a dilemma for thoracic
surgeons. Most of these patients are elderly and have poor
Figure 1 Survival and disease-free intervals of patients undergoing lobectomy and sublobar resection for solid-type, clinical stage IA,
non-small cell lung cancers. a. Recurrence-free survival. b. Overall survival.
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Sublobar resection has been an alternative treatment, and
its efficacy has been evaluated in several studies [10,11].
Ground-glass opacities (GGO) or GGO-predominant
lesions on chest CT are features of bronchioloalveolar car-
cinoma or adenocarcinoma, which are slowly growing and
noninvasive tumors [12]. Sublobar resection is appropriate
for these lesions [13-15]; however, the efficacy of sublobar
resection for solid-type lung cancer is controversial.
In 1995, a randomized trial was performed that com-
pared sublobar resection with lobectomy for clinical early
stage NSCLC [2]. Sublobar resection was associated with
high rates of recurrence and death. Landreneau et al.
compared wedge resection with lobectomy in 1997 [3].
Wedge resection failed to demonstrate equivalent results;
however, Kodama et al. demonstrated that sublobar
resection with lymph node dissection was not inferior
to lobectomy [16]. Because of advances in imaging study,
surgical technique and revised TNM classification, the
effect of sublobar resection has been evaluated for patients
with clinical T1a lung cancers again. Several studies found
no difference for recurrence and survival between patients
undergoing sublobar resection or lobectomy [4,17,18].Table 3 Univariate and multivariate analyses for predictors o
Variables Univariate
HR 95% CI
Cardiovascular disease 2.152 1.051 to 4.409
Sublobar resection 3.379 1.920 to 5.946
Visceral pleural invasion 3.281 1.628 to 6.612
Positive margin 2.692 1.148 to 6.314
Lymphatic vessel invasion 3.308 1.853 to 5.908
Lymph node metastasis 2.194 1.067 to 4.512
CI, confidence interval; HR, hazard ratio.Okada et al. compared segmentectomy with lobectomy
for tumors smaller than 2 cm, and found respective
5-year survival rates of 87.1% and 87.7% for segmentect-
omy and lobectomy. In recent study, randomized study
was conducted and sublobar resection is not inferior to
lobectomy for clinical stage IA lung cancer [19]. The recur-
rence rate was more common in the patients with sublobar
resection but not significantly and the survival was not dif-
ferent in their study.
Our study showed different results. High-risk patients
more frequently underwent sublobar resection, and sublo-
bar resection showed shorter disease-free interval and poor
survival. Furthermore, 19 patients (61.3%) in sublobar re-
section showed recurrence during the follow-up period.
Lung to lung metastasis (31.6%) was most common fol-
lowed by mediastinal lymph node metastasis (26.3%).
Lymph node metastasis is common in solid-type lung
cancers [20]. In our study, 15% of lobectomy patients
had lymph node metastases at the time of surgery in
clinical stage IA NSCLC. Lymphatic vessel invasion has
been found to be a prognostic factor [21]. Lymphatic
vessel invasion is associated with lymph node metastasis,
recurrence, and decreased survival. Funai et al. reportedf recurrence
Multivariate
P value HR 95% CI P value
0.036
<0.001 4.387 2.438 to 7.891 <0.001
0.001 3.142 1.510 to 6.538 0.002
0.023
<0.001 3.385 1.853 to 6.182 <0.001
0.033
Table 4 Univariate and multivariate analyses for predictors of survival
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age 1.050 1.010 to 1.091 0.014
Cardiovascular disease 3.501 1.550 to 7.906 0.003
Sublobar resection 3.236 1.525 to 6.868 0.002 3.224 1.312 to 7.924 0.011
Lymphatic vessel invasion 3.690 1.670 to 8.154 0.001 3.586 1.445 to 8.900 0.006
Number of positive LNs 1.272 1.095 to 1.478 0.002 1.214 1.022 to 1.442 0.028
N2 positive 5.123 1.716 to 15.297 0.003
CI, confidence interval; HR, hazard ratio; LN, lymph node; N2, mediastinal lymph node.
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nostic factor for early-stage lung cancers [22].
The proportion of solid component has been correlated
with malignant potential regardless of tumor size [23].
Our study results support this finding. Despite the early
stages of the solid-type tumors in our study, they had
aggressive behavior and were associated with several
prognostic pathologic features, including lymphatic ves-
sel invasion, pleural invasion, and occult lymph node
metastasis. In our study, sublobar resection failed to dem-
onstrate efficacy, even for tumors smaller than 2 cm. Lob-
ectomy provided longer disease-free-interval and survival.
Therefore, lobectomy with lymph node dissection remains
standard treatment for patients with solid-type early lung
cancers, regardless of tumor size.
Our study had limitations because it was small and non-
randomized, and positive margins were common among
the sublobar resections; however, neither recurrence nor
survival was associated with positive margins according toFigure 2 Overall Survival patients undergoing lobectomy and sublob
cancers smaller than 2 cm.multivariate analysis. Okami et al. found that sublobar re-
section for elderly patients provided good clinical out-
comes [24], but we did not compare sublobar resection
with lobectomy for high-risk patients, including patients
who were older or who had poor cardiopulmonary reserve.
Another limitation was that the number of resected lymph
nodes evaluated from patients undergoing sublobar resec-
tion was significantly lower than the number from lobec-
tomy patients [25,26].
Conclusions
In conclusion, solid-type lung cancers demonstrated ag-
gressive behavior, and there were numerous significant
pathologic prognostic factors in clinical stage IA NSCLC
from our study. Lymph node metastasis was common in
clinical stage IA NSCLC with a solid component. Lobec-
tomy with lymph node dissection remains the standard
surgical procedure for patients with solid-type, clinical
stage, IA NSCLC.ar resection for solid-type, clinical stage IA, non-small cell lung
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